You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
26 March 2024
BB BIOTECH AG: Dr. Thomas von Planta, buy
21 March 2024
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
21 February 2024
BB BIOTECH AG: Prof. Dr. Mads Krogsgaard Thomsen, buy
16 February 2024
BB Biotech AG publishes its 2023 annual report
14 February 2024
Investor interest returns – dividend yield remains high for 2024
19 January 2024
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
20 October 2023
BB Biotech AG publishes its interim report
BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
21 July 2023
BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
3 May 2023
BB BIOTECH AG: Creating blockbuster drugs using algorithms
21 April 2023
BB BIOTECH AG: Lackluster first quarter for biotech stocks
23 March 2023
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
17 February 2023
BB Biotech AG publishes its 2022 annual report
20 January 2023
BB Biotech AG closes the 2022 fiscal year with a loss
BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
8 December 2022
BB BIOTECH AG: Molecular strike force for the immune system
21 October 2022
BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
30 August 2022
BB BIOTECH AG: Moderna was just the beginning
22 July 2022
BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
24 May 2022
BB BIOTECH AG: Disruptive technologies are changing an entire industry
22 April 2022
BB BIOTECH AG: Increased investment level balanced by established core holdings
12 April 2022
BB Biotech AG concludes its share buyback program and launches a new buyback program
17 March 2022
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
26
Apr 24
Publication quarterly financial report (call-date Q1)
Jul 24
Publication half-yearly financial report
25
Oct 24
Publication quarterly financial report (call-date Q3)